FLT3 and acute myeloid leukemia: The LCS17 score could also support the identification of low-molecular risk (LMR) AML cases at diagnosis, as shown in a large training cohort comprising patients of all subtypes, including 9% LMR cases, i.e., patients with normal cytogenetics, NPM1 mutation and no FLT3-ITD [57].